Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism
Overview
Authors
Affiliations
Trastuzumab shows remarkable efficacy in treatment of ErbB2-positive breast cancers when used alone or in combination with other chemotherapeutics. However, acquired resistance develops in most treated patients, necessitating alternate treatment strategies. Increased aerobic glycolysis is a hallmark of cancer and inhibition of glycolysis may offer a promising strategy to preferentially kill cancer cells. In this study, we investigated the antitumor effects of trastuzumab in combination with glycolysis inhibitors in ErbB2-positive breast cancer. We found that trastuzumab inhibits glycolysis via downregulation of heat shock factor 1 (HSF1) and lactate dehydrogenase A (LDH-A) in ErbB2-positive cancer cells, resulting in tumor growth inhibition. Moreover, increased glycolysis via HSF1 and LDH-A contributes to trastuzumab resistance. Importantly, we found that combining trastuzumab with glycolysis inhibition synergistically inhibited trastuzumab-sensitive and -resistant breast cancers in vitro and in vivo, due to more efficient inhibition of glycolysis. Taken together, our findings show how glycolysis inhibition can dramatically enhance the therapeutic efficacy of trastuzumab in ErbB2-positive breast cancers, potentially useful as a strategy to overcome trastuzumab resistance.
Madoz-Gurpide J, Serrano-Lopez J, Sanz-Alvarez M, Morales-Gallego M, Rodriguez-Pinilla S, Rovira A Int J Mol Sci. 2025; 26(4).
PMID: 40004024 PMC: 11855744. DOI: 10.3390/ijms26041559.
Huang L, Zhao W, Sun L, Niu D, Zhu X, Jin C Front Oncol. 2025; 14:1493996.
PMID: 39876898 PMC: 11772165. DOI: 10.3389/fonc.2024.1493996.
Metabolomics-Driven Biomarker Discovery for Breast Cancer Prognosis and Diagnosis.
Kaur R, Gupta S, Kulshrestha S, Khandelwal V, Pandey S, Kumar A Cells. 2025; 14(1.
PMID: 39791706 PMC: 11720085. DOI: 10.3390/cells14010005.
Cheng H, Chen N, Chen W, Wu Z, Sun Y, Teng W J Headache Pain. 2024; 25(1):207.
PMID: 39587478 PMC: 11590346. DOI: 10.1186/s10194-024-01916-x.
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.
Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y Mol Cancer. 2024; 23(1):261.
PMID: 39574178 PMC: 11580516. DOI: 10.1186/s12943-024-02165-x.